CLINICAL TRIALS PROFILE FOR TOPOTECAN

505(b)(2) Clinical Trials for TOPOTECAN

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Combination	NCT00186888 ↗	Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma	Active, not recruiting	National Cancer Institute (NCI)	Phase 3	2005-04-07	Retinoblastoma is a childhood cancer which affects the retina of the eye. The retina is the light sensitive layer of tissue that lines the back of the eyeball; sends visual messages through the optic nerve to the brain. When only one eye is affected, this is known as unilateral retinoblastoma and when both eyes are affected, it is called bilateral retinoblastoma. Treatment for retinoblastoma is individualized for each patient and is based on the form and the stage of the disease (inside the eye or has moved outside). The main goal is always to cure the cancer, and save the life of the child. Treatments are also designed with the hope of saving the vision, while completely destroying the tumor. Therapies may involve surgery, chemotherapy, radiation, and other treatments called focal treatments. Focal treatments may be laser therapy, freezing, or heat treatments meant to shrink and kill the tumor. In this study, researchers want to investigate how different participants respond to different therapies that are individualized specifically for them. Participants will be divided into three main groups, depending on whether the disease is unilateral or bilateral, and the stage of the disease. One of the main objectives of the study is to investigate how advanced tumors in children with bilateral disease respond to a new combination of chemotherapy with topotecan and vincristine, with G-CSF support. In order to improve results, some children with very advanced disease may receive carboplatin chemotherapy given around the eye at the same time that they receive topotecan by vein. Also, because children with retinoblastoma are diagnosed so early in life and the vision may be significantly impaired, this study will investigate how children develop and how the brain adjusts and compensates for the visual deficits. Finally, this study also investigates the biology of retinoblastoma, in order to understand better how this cancer develops.
New Combination	NCT00186888 ↗	Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma	Active, not recruiting	St. Jude Children's Research Hospital	Phase 3	2005-04-07	Retinoblastoma is a childhood cancer which affects the retina of the eye. The retina is the light sensitive layer of tissue that lines the back of the eyeball; sends visual messages through the optic nerve to the brain. When only one eye is affected, this is known as unilateral retinoblastoma and when both eyes are affected, it is called bilateral retinoblastoma. Treatment for retinoblastoma is individualized for each patient and is based on the form and the stage of the disease (inside the eye or has moved outside). The main goal is always to cure the cancer, and save the life of the child. Treatments are also designed with the hope of saving the vision, while completely destroying the tumor. Therapies may involve surgery, chemotherapy, radiation, and other treatments called focal treatments. Focal treatments may be laser therapy, freezing, or heat treatments meant to shrink and kill the tumor. In this study, researchers want to investigate how different participants respond to different therapies that are individualized specifically for them. Participants will be divided into three main groups, depending on whether the disease is unilateral or bilateral, and the stage of the disease. One of the main objectives of the study is to investigate how advanced tumors in children with bilateral disease respond to a new combination of chemotherapy with topotecan and vincristine, with G-CSF support. In order to improve results, some children with very advanced disease may receive carboplatin chemotherapy given around the eye at the same time that they receive topotecan by vein. Also, because children with retinoblastoma are diagnosed so early in life and the vision may be significantly impaired, this study will investigate how children develop and how the brain adjusts and compensates for the visual deficits. Finally, this study also investigates the biology of retinoblastoma, in order to understand better how this cancer develops.
New Combination	NCT04661852 ↗	Cabozantinib With Topotecan-Cyclophosphamide	Recruiting	Dana-Farber Cancer Institute	Phase 1	2020-12-23	This research study is a clinical trial of a new combination of drugs as a possible treatment for relapsed/refractory Ewing sarcoma and/or osteosarcoma. - The names of the drugs are: - Cabozantinib - Topotecan - Cyclophosphamide - The names of the non-investigational supportive care drugs are: - Filgrastim, pegfilgrastim, or a related growth factor.

All Clinical Trials for TOPOTECAN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00001333 ↗	Phase I Study of Intrathecal Topotecan	Completed	National Cancer Institute (NCI)	Phase 1	1993-02-01	The purpose of this study is to determine the qualitative and quantitative toxicity of intrathecal topotecan, a topoisomerase I inhibitor, in patients with meningeal malignancies refractory to conventional therapy (radiation therapy and chemotherapy).
NCT00001335 ↗	New Therapeutic Strategies for Patients With Ewing's Sarcoma Family of Tumors, High Risk Rhabdomyosarcoma, and Neuroblastoma	Completed	National Cancer Institute (NCI)	Phase 2	1993-04-01	The prognosis for patients with metastatic Ewing's sarcoma family of tumors (ESF), rhabdomyosarcoma (RMS), and neuroblastoma (NBL) remains dismal, with less than 25% long-term disease-free survival. Though less grave, the prognosis for cure for other high-risk patients is approximately 50%. New treatment strategies, including the identification of highly active new agents, maximizing the dose intensity of the most active standard drugs, and the development of improved methods of consolidation to eradicate microscopic residual disease, are clearly needed to improve the outcome of these patients. This protocol will address these issues by commencing with a Phase II window, for the highest risk patients, to evaluate a series of promising drugs with novel mechanisms of action. All patients will then receive 5 cycles of dose-intensive "best standard therapy" with doxorubicin (adriamycin), vincristine, and cyclophosphamide (VAdriaC). Patients at high risk of relapse will continue onto a phase I consolidation regimen consisting of three cycles of dose-escalated Melphalan, Ifosfamide, Mesna, and Etoposide (MIME). Peripheral blood stem cell transfusions (PBSCT) and recombinant human G-CSF will be used as supportive care measures to allow maximal dose-escalation of this combination regimen.
NCT00002395 ↗	Safety and Effectiveness of Topotecan HCl to Treat HIV-Infected Patients With AIDS-Related Progressive Multifocal Leukoencephalopathy (PML)	Completed	SmithKline Beecham	Phase 2	1969-12-31	The purpose of this study is to see if it is safe and effective to give topotecan through a vein to treat HIV-infected patients with PML, an opportunistic (AIDS-related) infection caused by a virus that infects brain tissue and causes damage to the brain and the spinal cord. Topotecan fights HIV and the JC virus (the virus that causes PML) in laboratory experiments.

Clinical Trial Conditions for TOPOTECAN

Condition Name

Condition Name for TOPOTECAN
Intervention	Trials
Ovarian Cancer	81
Neuroblastoma	42
Small Cell Lung Cancer	39

Condition MeSH

Condition MeSH for TOPOTECAN
Intervention	Trials
Small Cell Lung Carcinoma	108
Ovarian Neoplasms	100
Lung Neoplasms	97

Clinical Trial Locations for TOPOTECAN

Trials by Country

Trials by Country for TOPOTECAN
Location	Trials
China	90
Australia	88
United Kingdom	79
Germany	73
Italy	68

Trials by US State

Trials by US State for TOPOTECAN
Location	Trials
California	112
New York	103
Ohio	100
Texas	100
Florida	94

Clinical Trial Progress for TOPOTECAN

Clinical Trial Phase

Clinical Trial Phase for TOPOTECAN
Clinical Trial Phase	Trials
PHASE3	22
PHASE2	11
PHASE1	5

Clinical Trial Status

Clinical Trial Status for TOPOTECAN
Clinical Trial Phase	Trials
Completed	243
Recruiting	72
Terminated	44

Clinical Trial Sponsors for TOPOTECAN

Sponsor Name

Sponsor Name for TOPOTECAN
Sponsor	Trials
National Cancer Institute (NCI)	139
GlaxoSmithKline	62
Children's Oncology Group	16

Sponsor Type

Sponsor Type for TOPOTECAN
Sponsor	Trials
Other	441
Industry	252
NIH	144

Last updated: April 25, 2026

Topotecan: Clinical Trials Update, Market Analysis, and 2025–2035 Projection

Topotecan is an established anti-cancer topoisomerase I inhibitor marketed in multiple formulations (notably IV topotecan for ovarian cancer and SCLC, and oral topotecan for ovarian cancer in some markets). Its clinical pipeline is now defined by incremental combination studies, formulation strategies, and new line-of-therapy positioning rather than late-stage “platform” breakthroughs.

---

What is the current clinical-trials landscape for topotecan?

Clinical development focus

Current activity centers on:

• Combination regimens to improve efficacy in ovarian cancer and small cell lung cancer (SCLC).
• New patient stratification (biomarker-enriched or histology- and prior-therapy-defined cohorts).
• Re-treatment and earlier-line positioning where regulatory pathways permit expansion beyond established refractory settings.

Why the pipeline is structurally “mature”

Topotecan has long-standing mechanism-of-action knowledge and standard-of-care inclusion in multiple jurisdictions. That typically shifts trial economics toward:

• Smaller randomized studies or cohorts designed around response endpoints,
• Escalation through combinations (with companion drug sponsors driving trial funding),
• Regimen optimization for tolerability and schedule adherence.

Practical implication for investors and R&D

Clinical trial activity tends to produce:

• Label-expansion outcomes (subset approvals, line-of-therapy updates, or expanded indication language), and
• Evidence that strengthens usage in refractory or post-platinum disease settings.

---

What do recent trial and regulatory signals imply for topotecan’s competitiveness?

Competitive position

Topotecan’s competitiveness depends less on single-agent potency and more on:

• Where it fits in sequencing against newer agents (antibody-drug conjugates, PARP inhibitors, and immune-oncology combinations),
• Tolerability management (myelosuppression is the key operational barrier for combination designs),
• Access and cost in key markets, where generics have largely set pricing floors.

Formulation and route matter

Clinical development and real-world use diverge across routes:

• IV topotecan retains anchor status in settings where IV regimens are standard.
• Oral topotecan supports adherence and logistics convenience in markets and health systems where oral regimens are reimbursed.

---

How big is the topotecan opportunity today?

Market structure

Topotecan is sold globally but with price compression from generic penetration. Commercial value is driven by:

• Maintenance of use in label-indicated refractory settings,
• Uptake in combination regimens where clinicians select topotecan for a mechanistic fit,
• Ongoing procurement cycles through hospital formularies.

Serviceable addressable segments

Primary commercial demand concentrates in:

• Ovarian cancer (especially relapsed or refractory disease settings),
• SCLC (particularly relapsed disease),
• Indirect demand in trials that translate into clinical guidelines and formularies.

---

What drives revenue and utilization (and what limits it)?

Key revenue drivers

• Continued inclusion in oncology treatment algorithms for refractory ovarian cancer and SCLC.
• Combination regimens that keep topotecan relevant when new agents reduce reliance on older cytotoxics alone.
• Hospital procurement and standardized chemotherapy pathways.

Key headwinds

• Generic competition compresses unit prices.
• New-generation regimens displace cytotoxics in earlier lines where response and survival benefits are stronger.
• Myelosuppression and schedule burden constrain trial and real-world adoption in combination contexts.

---

Market projection: 2025–2035 for topotecan

Projection logic

Given:

• Mature mechanism and mature clinical positioning,
• Generic pricing pressure,
• Ongoing, but largely incremental, trial activity,

the projection assumes a low-growth to mid-single-digit CAGR in revenue (value) driven by utilization stability, with modest uplift from combination evidence and regional reimbursement cycles.

Base-case revenue outlook (global)

The market’s shape is driven by price erosion offset by continued clinical need.

Period	Expected utilization trend	Expected price trend	Net revenue trend
2025–2027	Stable to slight growth	Flat to down	Low single-digit growth
2028–2031	Modest growth via line-of-therapy shifts	Downward pressure	Mid single-digit ceiling
2032–2035	Gradual stabilization	Continues compression	Low single-digit growth

Best- and downside-case scenarios

Scenario	What changes	Revenue impact vs base
Upside	Label expansions through combination data and stronger guideline placement	+5 to +12% by 2030
Base	Continued use in refractory settings; no major single-agent re-platforming	Reference
Downside	Faster displacement in certain lines by ADCs/PARPi-based regimens	-10 to -25% by 2030

---

What is the investment and R&D takeaway from the clinical and market picture?

Where value can still be created

Topotecan’s economic value creation is most plausible through:

• Regimen differentiation (topotecan + specific partner drugs and schedules that show clinically meaningful benefit),
• Operational improvements (tolerability protocols and administration pathways that reduce treatment interruptions),
• Formulation strategy that sustains oral uptake where reimbursement supports it.

Where value creation is hardest

• Large-scale single-agent “breakthrough” claims are unlikely given known efficacy ceiling and generic market structure.
• New entrants must overcome price sensitivity and established hospital purchasing preferences.

---

Key Takeaways

• Topotecan clinical activity is now largely about combination regimens, sequencing, and patient selection rather than new mechanism platforms.
• Market growth is constrained by generic pricing compression, so upside relies on label expansions and guideline reinforcement from ongoing evidence.
• Base-case outlook supports low single-digit to low-mid single-digit revenue growth through 2035, with upside possible if combination trials translate into broader clinical adoption.

---

FAQs

1) Is topotecan’s pipeline currently about new drugs or about regimen optimization?

It is predominantly regimen and positioning optimization through combination trials and patient subset definitions.

2) What cancers drive most topotecan demand?

Commercial demand concentrates on ovarian cancer and SCLC.

3) Why does market value not track strongly with clinical innovation?

Because generic competition compresses prices, so revenue depends more on utilization stability and line-of-therapy placement than on incremental efficacy gains.

4) What clinical limitation most affects combination strategy?

Myelosuppression and schedule burden, which influence tolerability endpoints and feasibility in multi-drug regimens.

5) What is the most realistic route to upside for topotecan over the next decade?

Label expansions and stronger guideline usage supported by combination outcomes and practical administration protocols.

---

References (APA)

[1] National Cancer Institute. (n.d.). Topotecan. https://www.cancer.gov
[2] U.S. Food and Drug Administration. (n.d.). Topotecan (label information and approvals). https://www.accessdata.fda.gov
[3] European Medicines Agency. (n.d.). Topotecan (assessment and EPAR documents). https://www.ema.europa.eu
[4] PubMed. (n.d.). Topotecan clinical trials (ovarian cancer, small cell lung cancer). https://pubmed.ncbi.nlm.nih.gov